<p>在今天發佈的一份報告中，Stifel Nicolaus 的 Stephen Willey 對 Pyxis Oncology 維持了買入評級，目標價為 9.00 美元。</p>
<h3>享受 TipRanks Premium 50% 折扣，信心投資</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的位置</li>
</ul>
<p>根據 TipRanks，Willey 是一位四星分析師，平均回報率為 7.6%，成功率為 41.89%。Willey 關注醫療保健領域，重點關注 Zymeworks、Nurix Therapeutics 和 Pyxis Oncology 等股票。</p>
<p>除了 Stifel Nicolaus，Pyxis Oncology 還在今天的報告中獲得了 LifeSci Capital 的 Sam Slutsky 的買入評級。然而，William Blair 昨天重申了對 Pyxis Oncology (NASDAQ: PYXS) 的持有評級。</p>

PYXS

<p>Stifel Nicolaus 分析師 Stephen Willey 對 Pyxis Oncology 維持買入評級，目標價為 9.00 美元。Willey 是 TipRanks 上的四星分析師，專注於醫療保健領域。LifeSci Capital 的 Sam Slutsky 也發佈了買入評級，而 William Blair 則重申了對 Pyxis Oncology 的持有評級</p>

<p>In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Pyxis Oncology, with a price target of $9.00.</p>
<div class="lb-trans"><p>在今天發佈的一份報告中，Stifel Nicolaus 的 Stephen Willey 對 Pyxis Oncology 維持了買入評級，目標價為 9.00 美元。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，信心投資</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的位置</li>
</ul>
</div><p>According to TipRanks, Willey is a 4-star analyst with an average return of 7.6% and a 41.89% success rate. Willey covers the Healthcare sector, focusing on stocks such as Zymeworks, Nurix Therapeutics, and Pyxis Oncology.</p>
<div class="lb-trans"><p>根據 TipRanks，Willey 是一位四星分析師，平均回報率為 7.6%，成功率為 41.89%。Willey 關注醫療保健領域，重點關注 Zymeworks、Nurix Therapeutics 和 Pyxis Oncology 等股票。</p>
</div><p>In addition to Stifel Nicolaus, Pyxis Oncology also received a Buy from LifeSci Capital’s Sam Slutsky in a report issued today. However, yesterday, William Blair reiterated a Hold rating on Pyxis Oncology (NASDAQ: PYXS).</p>
<div class="lb-trans"><p>除了 Stifel Nicolaus，Pyxis Oncology 還在今天的報告中獲得了 LifeSci Capital 的 Sam Slutsky 的買入評級。然而，William Blair 昨天重申了對 Pyxis Oncology (NASDAQ: PYXS) 的持有評級。</p>
</div>

Stifel Nicolaus 維持對 Pyxis Oncology（PYXS）的買入評級